Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation

T. Fujino, L. Nguyen, S. Yoda, M. Yu, H. Mizuta, L. Bigot, C. Nobre, A. Tangpeerachaikul, H. E. Pelish, L. Friboulet, J. Lee, B. Cho, A. N. Hata

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)
    Original languageEnglish
    Pages (from-to)S78-S79
    JournalEuropean Journal of Cancer
    Volume174
    DOIs
    Publication statusPublished - 1 Oct 2022

    Cite this